{"protocolSection": {"identificationModule": {"nctId": "NCT02507011", "orgStudyIdInfo": {"id": "1504M69361"}, "organization": {"fullName": "University of Minnesota", "class": "OTHER"}, "briefTitle": "Beta-blockers in Pulmonary Arterial Hypertension", "officialTitle": "Beta-blockers in Pulmonary Arterial Hypertension - A Phase 2 Double-Blind, Placebo-Controlled, Crossover Study Evaluating the Efficacy, and Safety of Carvedilol for Right Ventricular Dysfunction in Pulmonary Arterial Hypertension"}, "statusModule": {"statusVerifiedDate": "2020-05", "overallStatus": "TERMINATED", "whyStopped": "Recruitment", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2016-01-31", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2019-07-01", "type": "ACTUAL"}, "completionDateStruct": {"date": "2019-07-01", "type": "ACTUAL"}, "studyFirstSubmitDate": "2015-07-22", "studyFirstSubmitQcDate": "2015-07-22", "studyFirstPostDateStruct": {"date": "2015-07-23", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2020-05-28", "resultsFirstSubmitQcDate": "2020-05-28", "resultsFirstPostDateStruct": {"date": "2020-06-16", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2020-05-28", "lastUpdatePostDateStruct": {"date": "2020-06-16", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "University of Minnesota", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "The investigators will conduct a, randomized, phase 2, placebo-controlled, double-blinded, crossover trial of carvedilol in 26 PAH patients with World Health Organization functional class II or III symptoms and RV ejection fraction (EF) \\< 45% for 6 months.", "detailedDescription": "Adult PAH patients on a stable dose of an approved PAH medication will undergo the following baseline assessments: cardiac magnetic resonance imaging (MRI), right heart catheterization (RHC), echocardiogram, 6-minute walk test (6-MWT), plasma NT-ProBNP (biomarkers of RV function) and serum catecholamine (measure of sympathetic activation), and quality of life. Patients will be randomized to carvedilol (3.125 mg bid and escalated to 9.375 mg bid, as tolerated, over 3 months) or placebo in a 1:1 fashion. After 6 months, testing is repeated and patients are crossed over to the alternate treatment. Testing is repeated at the end of the study (month 13)."}, "conditionsModule": {"conditions": ["Pulmonary Arterial Hypertension"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 2, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Carvedilol First", "type": "EXPERIMENTAL", "description": "Crossover Design: Participants receive Carvedilol first and placebo second", "interventionNames": ["Drug: Carvedilol", "Drug: Placebo"]}, {"label": "Placebo First", "type": "PLACEBO_COMPARATOR", "description": "Crossover Design: Participants receive placebo first and Carvedilol second", "interventionNames": ["Drug: Carvedilol", "Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "Carvedilol", "description": "Beta-adrenergic receptor blocker", "armGroupLabels": ["Carvedilol First", "Placebo First"], "otherNames": ["Beta-blockers"]}, {"type": "DRUG", "name": "Placebo", "description": "Placebo", "armGroupLabels": ["Carvedilol First", "Placebo First"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Mean Change in Right Ventricular Ejection Fraction as Measured by Cardiac MRI", "timeFrame": "6 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Age \\> 18 years\n* WHO category 1 pulmonary arterial hypertension (Nice 2013)\n* WHO functional class II-III\n* RVEF by cardiac MRI \\< 45%\n* Stable on PAH-specific therapy as defined by no change in PAH-specific treatment and functional class in the past 3 months. Patient can be on either mono or combination PAH-specific therapy\n\nExclusion Criteria:\n\n* Subjects will be excluded from participation in the study if any of the following conditions exist:\n* Significant persistent bradycardia (resting heart rate \\< 60 bpm) without a permanent pacemaker\n* Second or third degree AV block without a permanent pacemaker\n* Significant sinus tachycardia (resting heart rate \\> 110 bpm)\n* Use of anti-arrhythmic drugs\n* Hypotension defined as systolic blood pressure \\< 100 mmHg at the time of enrollment\n* Significant illness in the past 30 days requiring hospitalization\n* Acute decompensated right heart failure within past 30 days\n* Known allergy or intolerance to carvedilol or other \u03b2 blockers\n* Cardiac index \\< 2 l/min/m2 or right atrial pressure \\> 15 mm Hg by right heart catheterization within last 3 months\n* Asthma\n* Positive pregnancy test in patients of child bearing-potential", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Thenappan Thenappan, MD", "affiliation": "University of Minnesota", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "University of Minnesota Medical Center", "city": "Minneapolis", "state": "Minnesota", "zip": "55455", "country": "United States", "geoPoint": {"lat": 44.97997, "lon": -93.26384}}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Carvedilol First, Then Placebo", "description": "Participants in this arm received Carvedilol first"}, {"id": "FG001", "title": "Placebo First, Then Carvedilol", "description": "Participants in this arm received placebo first"}], "periods": [{"title": "First Intervention", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}, {"title": "Second Intervention", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "All Participants", "description": "Crossover Design: All participants pooled at baseline"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "2"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "1"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "1"}]}]}]}, {"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "61.5", "spread": "10.6"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "2"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "0"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "2"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Mean Change in Right Ventricular Ejection Fraction as Measured by Cardiac MRI", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percent", "timeFrame": "6 months", "groups": [{"id": "OG000", "title": "Carvedilol", "description": "Beta Blocker\n\nCarvedilol: Beta-adrenergic receptor blocker\n\nPlacebo: Placebo"}, {"id": "OG001", "title": "Placebo", "description": "General Placebo\n\nCarvedilol: Beta-adrenergic receptor blocker\n\nPlacebo: Placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "2"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "10", "spread": "4"}, {"groupId": "OG001", "value": "2.5", "spread": "2"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "13 months", "eventGroups": [{"id": "EG000", "title": "Carvedilol", "description": "Beta Blocker\n\nCarvedilol: Beta-adrenergic receptor blocker\n\nPlacebo: Placebo", "deathsNumAffected": 0, "deathsNumAtRisk": 2, "seriousNumAffected": 1, "seriousNumAtRisk": 2, "otherNumAffected": 1, "otherNumAtRisk": 2}, {"id": "EG001", "title": "Placebo", "description": "General Placebo\n\nCarvedilol: Beta-adrenergic receptor blocker\n\nPlacebo: Placebo", "deathsNumAffected": 0, "deathsNumAtRisk": 2, "seriousNumAffected": 1, "seriousNumAtRisk": 2, "otherNumAffected": 2, "otherNumAtRisk": 2}], "seriousEvents": [{"term": "HF Exaceberation/Electrolyte Imbalance", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 1, "numAtRisk": 2}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2}]}], "otherEvents": [{"term": "Fatigue", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2}]}, {"term": "Hypotension", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}]}, {"term": "Fluid Retention", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2}]}, {"term": "Constipation", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG001", "numEvents": 2, "numAffected": 1, "numAtRisk": 2}]}, {"term": "Gastroenteritis", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG001", "numEvents": 2, "numAffected": 1, "numAtRisk": 2}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": true}, "pointOfContact": {"title": "Thenappan Thenappan, MD", "organization": "University of Minnesota", "email": "cvheart@umn.edu", "phone": "612-625-2191"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "ICF", "hasProtocol": false, "hasSap": false, "hasIcf": true, "label": "Informed Consent Form", "date": "2017-10-12", "uploadDate": "2020-04-09T09:44", "filename": "ICF_000.pdf", "size": 345947}, {"typeAbbrev": "Prot_SAP", "hasProtocol": true, "hasSap": true, "hasIcf": false, "label": "Study Protocol and Statistical Analysis Plan", "date": "2017-10-12", "uploadDate": "2020-05-28T10:32", "filename": "Prot_SAP_001.pdf", "size": 715233}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-26"}, "conditionBrowseModule": {"meshes": [{"id": "D000081029", "term": "Pulmonary Arterial Hypertension"}, {"id": "D000065627", "term": "Familial Primary Pulmonary Hypertension"}, {"id": "D000006973", "term": "Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}, {"id": "D000006976", "term": "Hypertension, Pulmonary"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}], "browseLeaves": [{"id": "M2261", "name": "Pulmonary Arterial Hypertension", "asFound": "Pulmonary Arterial Hypertension", "relevance": "HIGH"}, {"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M20824", "name": "Ventricular Dysfunction", "relevance": "LOW"}, {"id": "M20601", "name": "Ventricular Dysfunction, Right", "relevance": "LOW"}, {"id": "M10027", "name": "Hypertension, Pulmonary", "relevance": "LOW"}, {"id": "M30541", "name": "Familial Primary Pulmonary Hypertension", "asFound": "Pulmonary Arterial Hypertension", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "T4807", "name": "Pulmonary Arterial Hypertension", "asFound": "Pulmonary Arterial Hypertension", "relevance": "HIGH"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000077261", "term": "Carvedilol"}], "ancestors": [{"id": "D000000319", "term": "Adrenergic beta-Antagonists"}, {"id": "D000018674", "term": "Adrenergic Antagonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000000975", "term": "Antioxidants"}, {"id": "D000020011", "term": "Protective Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000058668", "term": "Adrenergic alpha-1 Receptor Antagonists"}, {"id": "D000000317", "term": "Adrenergic alpha-Antagonists"}], "browseLeaves": [{"id": "M1718", "name": "Carvedilol", "asFound": "Depressive Disorder", "relevance": "HIGH"}, {"id": "M3671", "name": "Adrenergic beta-Antagonists", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M20755", "name": "Adrenergic Antagonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M4292", "name": "Antioxidants", "relevance": "LOW"}, {"id": "M21869", "name": "Protective Agents", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M29194", "name": "Adrenergic alpha-1 Receptor Antagonists", "relevance": "LOW"}, {"id": "M3669", "name": "Adrenergic alpha-Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}]}}, "hasResults": true}